Better COVID Stock: Merck vs. Pfizer

As two of the world's largest pharmaceutical companies, Pfizer (NYSE: PFE) and Merck (NYSE: MRK) are fierce and heavyweight competitors in the market for coronavirus medicines. While both are firmly profitable, neither company has outperformed the market over the last decade, nor in the past three years. 

But, with the considerable hype and massive new revenue generated by their coronavirus projects, that could change. Let's evaluate the prospects of each of these competitors. 

Image source: Getty Images.

Continue reading

Source Fool.com